Enveric Biosciences, Inc. (ENVB) Stock
Healthcare · Biotechnology · US
$3.88
-24.81%
Last updated Jun 18, 2026 23:53 UTC
ENVB Key Statistics
Market Cap$2.32M
P/E (TTM)0.00
P/S (TTM)—
P/B (TTM)0.99
Revenue (TTM)$0.00
EPS (TTM)$-14,610.70
Dividend Yield—
ROE (TTM)-255.44%
Net Margin0.00%
Gross Margin0.00%
52W High$7.88
52W Low$1.71
Analyst ViewBuy
Price Target—
Employees5
Volume2,797,982
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
CEO: Joseph Edward Tucker. Company website
See ENVB live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ENVB in Terminal See plans